Leavell Investment Management Inc. Sells 6,450 Shares of Edwards Lifesciences Co. (NYSE:EW)

Leavell Investment Management Inc. trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 65.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,473 shares of the medical research company's stock after selling 6,450 shares during the quarter. Leavell Investment Management Inc.'s holdings in Edwards Lifesciences were worth $257,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Harbor Capital Advisors Inc. grew its position in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after acquiring an additional 273 shares during the period. Nordea Investment Management AB lifted its stake in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in shares of Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $3,702,000. Finally, Avanza Fonder AB purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $4,845,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

NYSE EW traded down $0.08 on Tuesday, reaching $76.11. The company's stock had a trading volume of 1,613,707 shares, compared to its average volume of 4,464,341. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market cap of $44.89 billion, a PE ratio of 10.98, a PEG ratio of 3.64 and a beta of 1.10. The firm's 50 day moving average is $72.78 and its two-hundred day moving average is $69.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock valued at $2,002,829 over the last ninety days. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Truist Financial reissued a "hold" rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Piper Sandler lifted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.